77 related articles for article (PubMed ID: 19168340)
1. An economic analysis of pharmacological treatment of COPD in Spain.
Miravitlles M; Brosa M; Velasco M; Crespo C; Gobartt E; Diaz S; González-Rojas N
Respir Med; 2009 May; 103(5):714-21. PubMed ID: 19168340
[TBL] [Abstract][Full Text] [Related]
2. Costs of chronic obstructive pulmonary disease in relation to compliance with guidelines: a study in the primary care setting.
Miravitlles M; Sicras A; Crespo C; Cuesta M; Brosa M; Galera J; Lahoz R; Lleonart M; Riera MI
Ther Adv Respir Dis; 2013 Jun; 7(3):139-50. PubMed ID: 23653458
[TBL] [Abstract][Full Text] [Related]
3. [Costs of chronic obstructive pulmonary disease in patients treated in ambulatory care in Poland].
Jahnz-Różyk K; Targowski T; From S; Faluta T; Borowiec L
Pneumonol Alergol Pol; 2011; 79(5):337-42. PubMed ID: 21861257
[TBL] [Abstract][Full Text] [Related]
4. Costs of chronic obstructive pulmonary disease (COPD) in Italy: the SIRIO study (social impact of respiratory integrated outcomes).
Dal Negro RW; Tognella S; Tosatto R; Dionisi M; Turco P; Donner CF
Respir Med; 2008 Jan; 102(1):92-101. PubMed ID: 17881206
[TBL] [Abstract][Full Text] [Related]
5. Cost analysis of chronic obstructive pulmonary disease in a tertiary care setting in Taiwan.
Chiang CH
Respirology; 2008 Sep; 13(5):689-94. PubMed ID: 18513247
[TBL] [Abstract][Full Text] [Related]
6. Risk of hospitalizations/emergency department visits and treatment costs associated with initial maintenance therapy using fluticasone propionate 500 microg/salmeterol 50 microg compared with ipratropium for chronic obstructive pulmonary disease in older adults.
Blanchette CM; Akazawa M; Dalal A; Simoni-Wastila L
Am J Geriatr Pharmacother; 2008 Aug; 6(3):138-46. PubMed ID: 18775388
[TBL] [Abstract][Full Text] [Related]
7. Retrospective incremental cost analysis of a hospital-based COPD Disease Management Programme in Sweden.
Tunsäter A; Moutakis M; Borg S; Persson U; Strömberg L; Nielsen AL
Health Policy; 2007 May; 81(2-3):309-19. PubMed ID: 16904788
[TBL] [Abstract][Full Text] [Related]
8. Direct medical costs of COPD--an excess cost approach based on two population-based studies.
Menn P; Heinrich J; Huber RM; Jörres RA; John J; Karrasch S; Peters A; Schulz H; Holle R;
Respir Med; 2012 Apr; 106(4):540-8. PubMed ID: 22100535
[TBL] [Abstract][Full Text] [Related]
9. Burden of chronic obstructive pulmonary disease in Medicare beneficiaries residing in long-term care facilities.
Simoni-Wastila L; Blanchette CM; Qian J; Yang HW; Zhao L; Zuckerman IH; Pak GH; Silver H; Dalal AA
Am J Geriatr Pharmacother; 2009 Oct; 7(5):262-70. PubMed ID: 19948302
[TBL] [Abstract][Full Text] [Related]
10. Economic assessment of early initiation of inhaled corticosteroids in chronic obstructive pulmonary disease using propensity score matching.
Akazawa M; Biddle AK; Stearns SC
Clin Ther; 2008; 30 Spec No():1003-16. PubMed ID: 18640475
[TBL] [Abstract][Full Text] [Related]
11. Evaluating the pharmacoeconomic effect of adding tiotropium bromide to the management of chronic obstructive pulmonary disease patients in Singapore.
Lee KH; Phua J; Lim TK
Respir Med; 2006 Dec; 100(12):2190-6. PubMed ID: 16635566
[TBL] [Abstract][Full Text] [Related]
12. [Costs of exacerbations of chronic obstructive pulmonary disease in primary and secondary care in 2007--results of multicenter Polish study].
Jahnz-Rózyk K; Targowski T; From S
Pol Merkur Lekarski; 2009 Mar; 26(153):208-14. PubMed ID: 19388534
[TBL] [Abstract][Full Text] [Related]
13. Cost impact of COPD in Japan: opportunities and challenges?
Nishimura S; Zaher C
Respirology; 2004 Nov; 9(4):466-73. PubMed ID: 15612957
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of fluticasone propionate/salmeterol (500/50 microg) in the treatment of COPD.
Earnshaw SR; Wilson MR; Dalal AA; Chambers MG; Jhingran P; Stanford R; Mapel DW
Respir Med; 2009 Jan; 103(1):12-21. PubMed ID: 19010652
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of healthcare utilization and health status of patients with Parkinson's disease treated with deep brain stimulation of the subthalamic nucleus.
Spottke EA; Volkmann J; Lorenz D; Krack P; Smala AM; Sturm V; Gerstner A; Berger K; Hellwig D; Deuschl G; Freund HJ; Oertel WH; Dodel RC
J Neurol; 2002 Jun; 249(6):759-66. PubMed ID: 12111311
[TBL] [Abstract][Full Text] [Related]
16. The economic burden of chronic obstructive pulmonary disease (COPD) in a U.S. Medicare population.
Menzin J; Boulanger L; Marton J; Guadagno L; Dastani H; Dirani R; Phillips A; Shah H
Respir Med; 2008 Sep; 102(9):1248-56. PubMed ID: 18620852
[TBL] [Abstract][Full Text] [Related]
17. Economic aspects of antimicrobial therapy of acute exacerbations of COPD.
Simoens S; Decramer M; Laekeman G
Respir Med; 2007 Jan; 101(1):15-26. PubMed ID: 16650975
[TBL] [Abstract][Full Text] [Related]
18. Assessing the costs of chronic obstructive pulmonary disease: the state medicaid perspective.
Marton JP; Boulanger L; Friedman M; Dixon D; Wilson J; Menzin J
Respir Med; 2006 Jun; 100(6):996-1005. PubMed ID: 16288858
[TBL] [Abstract][Full Text] [Related]
19. Comparison of hospitalizations, emergency department visits, and costs in a historical cohort of Texas Medicaid patients with chronic obstructive pulmonary disease, by initial medication regimen.
Rascati KL; Akazawa M; Johnsrud M; Stanford RH; Blanchette CM
Clin Ther; 2007 Jun; 29(6):1203-13. PubMed ID: 17692734
[TBL] [Abstract][Full Text] [Related]
20. The cost of treating patients with COPD in Denmark--a population study of COPD patients compared with non-COPD controls.
Bilde L; Rud Svenning A; Dollerup J; Baekke Borgeskov H; Lange P
Respir Med; 2007 Mar; 101(3):539-46. PubMed ID: 16889949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
